证券代码：688580 证券简称：伟思医疗 公告编号：2025-045 一、交易概述 南京伟思医疗科技股份有限公司 关于出售资产的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 交易简要内容:南京伟思医疗科技股份有限公司（以下简称："公司"或"伟思医疗"）拟以总价人民币 11,900 万元的价格，将其持有的位于南京市雨花台区宁双路19号9幢 的房屋及楼宇部分配套固定资产 （以下简称"标的资产"）转让给江苏云智汇创业投资有限公司（以下简称"本次交易"）。 ● 本次交易不构成关联交易 ● 本次交易不构成重大资产重组 ● 交易实施尚需履行的审批及其他相关程序：本次交易已经公司第四届董事会第八次会议审议通过，根 据《上海证券交易所科创板股票上市规则》的规定，该议案无需提交股东会审议。后续交易双方将按照 签署的《南京市存量房买卖合同》、《固定资产买卖合同》约定办理资产交付等事宜。 ● 风险提示：经公司初步估算，本次交易预计对公司2026年度归属于上市公司股东的净利润影响金额约 为1,000万元（未经审计），对2 ...

伟思医疗主要产品为康复医疗设备。2025年前三季度，伟思医疗营业收入为3.26亿元，同比增长 11.58%；归属于上市公司股东的净利润为1.02亿元，同比增长30.68%。 该资产截至2025年9月30日的账面净值为7994.86万元。 伟思医疗方面表示，本次交易预计对公司2026年度归属于上市公司股东的净利润影响金额约为1000万元 （未经审计），对2025年当期营业收入及净利润无任何影响。公司全新总部——"伟思医疗总部研发经 济园"（位于南京市雨花台区硕果路1号）已顺利通过竣工验收，全面具备高效办公与运营条件，公司计 划于2026年上半年完成整体搬迁。 12月22日晚，科创板上市公司伟思医疗（688580.SH）发布公告称，拟以总价1.19亿元的价格，将现在 的总部资产转让给江苏云智汇创业投资有限公司，目的在优化资产结构、提升资源配置效率并增强资金 流动性。 伟思医疗此次拟转让的资产是南京市雨花台区宁双路19号9幢的房屋及楼宇部分配套固定资产。 （文章来源：中国经营报） ...

（记者 曾健辉） 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 截至发稿，伟思医疗市值为45亿元。 每经头条（nbdtoutiao）——新能源重卡爆单了，11月销量同比增长178%！两班倒都供不应求，客户直 接进厂催单，这情景十年难遇 每经AI快讯，伟思医疗（SH 688580，收盘价：47.06元）12月22日晚间发布公告称，南京伟思医疗科技 股份有限公司拟以总价人民币1.19亿元的价格，将其持有的位于南京市雨花台区宁双路19号9幢的房屋 及楼宇部分配套固定资产转让给江苏云智汇创业投资有限公司。 2024年1至12月份，伟思医疗的营业收入构成为：医疗器械占比95.03%，其他占比3.79%，其他业务占 比1.18%。 每日经济新闻 ...

Group 1 - Rongchang Biotech plans to repurchase shares worth between 20 million and 40 million yuan, with a maximum price of 95 yuan per share, aiming to buy back approximately 21,050 to 42,110 shares, representing about 0.04% to 0.07% of total share capital [1] - Nanya New Materials intends to raise no more than 900 million yuan through a private placement for AI computing power-based high-frequency high-speed copper-clad laminate R&D and working capital [2] - Xiechuang Data has signed a strategic cooperation agreement with Ping An Financial Leasing, aiming for a cooperation scale of 2 billion yuan over three years [3] Group 2 - Chuangshi Technology's controlling shareholder is under investigation and has been placed under detention, having resigned from all positions in the company [4] - Deep Kangjia A has reported overdue shareholder loans to Yikang Technology and Chuzhou Kangxin, totaling approximately 233 million yuan and 395 million yuan respectively, due to repayment issues [5] - Ningbo Yuanyang announced the resignation of two directors due to work adjustments [6] Group 3 - China Merchants Energy has delivered the world's first methanol dual-fuel VLCC oil tanker, with 15 oil tanker orders in hand [7] - Tianyu Co., Ltd. has received a drug registration certificate for hydrochloride trazodone tablets, which are used for treating depression [8] - Haizheng Pharmaceutical has received FDA approval for clinical trials of HS387 tablets for treating advanced solid tumors [9] Group 4 - Warner Pharmaceuticals has obtained a drug registration certificate for isoproterenol hydrochloride injection, used for treating shock and complete atrioventricular block [10] - Hekang New Energy's subsidiary received a government subsidy of 1.5 million yuan, which accounts for 14.57% of the company's latest audited net profit [11] - Duku Culture is planning a change in company control, with stock suspension expected for no more than two trading days [12] Group 5 - Haisco has received acceptance for an IND application for HSK46575 tablets for prostate cancer treatment [13] - *ST Xinyan is executing a capital reserve transfer to increase share capital, resulting in a stock suspension [14] - Nanjing Public Utilities is transferring a 45% stake in a subsidiary for 23.6443 million yuan [15] Group 6 - Action Education plans to repurchase shares worth between 20 million and 25 million yuan, with a maximum price of 45 yuan per share [16] - Bai'ao Tai has received government subsidies totaling 29 million yuan [18] - Weisi Medical intends to sell assets worth 119 million yuan, expecting a profit impact of approximately 10 million yuan [19] Group 7 - Tongyu Communications plans to increase capital by 10 million yuan to introduce investment from Wuchuang Institute [20] - Dongtu Technology's subsidiary is introducing strategic investor Guofeng Investment Fund with a capital increase of 11 million yuan [21] - China General Nuclear Power Technology's shareholder is facing a judicial auction of 2.91% of the company's shares [22] Group 8 - Nanshan Aluminum plans to repurchase shares worth between 300 million and 600 million yuan, with a maximum price of 7.52 yuan per share [23] - Yipin Hong's controlling shareholder has committed to transferring 9.07% equity in Arthrosi without compensation [24] - Sanli Pharmaceutical has signed a technology transfer contract worth 200 million yuan with Hainan University [25] Group 9 - Xin Nuo Wei plans to jointly invest 450 million yuan with Zhongqi Pharmaceutical to establish a joint venture focusing on innovative metabolic drugs [26] - Li Qun Co. has been approved to issue 1 billion yuan in medium-term notes to optimize debt structure and supplement working capital [27] - Dongfang Ocean's subsidiary has received a medical device registration certificate for a procalcitonin test kit [28] Group 10 - Tibet Mining's chairman has resigned due to work adjustments [29] - Wantai Biological's subsidiary has been shortlisted for a national immunization program vaccine procurement project, with a bid price of 27.5 yuan [30] - Xingfu Blue Sea has appointed Zhang Chen as the new deputy general manager [31] Group 11 - Changyuan Donggu has elected Li Yixuan as the vice chairman of the board [32] - Ningbo Huaxiang's subsidiary has signed a strategic cooperation agreement with Dahuang Robotics for collaboration in humanoid robot development [33] - Yongda Co. has been pre-selected for a procurement project worth approximately 350 million yuan [34] Group 12 - Fuan Pharmaceutical's subsidiary has received a drug registration certificate for hydrochloride trazodone tablets [35] - Nanjing Food reported a 71.03% year-on-year decrease in net profit for November due to rising raw material costs [36] - Changqing Technology's special polymer monomer project has commenced production [37]

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 伟思医疗(688580.SH)公告称，公司拟以总价1.19亿元的价格，将持有的位于南京市雨花台区宁双路19号 9幢的房屋及楼宇部分配套固定资产，转让给江苏云智汇创业投资有限公司。此次交易预计对公司2026 年度归属于上市公司股东的净利润的影响金额约为1000万元。 ...

Core Viewpoint - Weisi Medical (688580) announced the transfer of its property and associated fixed assets in Nanjing for a total price of 119 million yuan, aiming to optimize asset utilization and support its strategic goals [1] Group 1: Transaction Details - The company plans to sell its property located at No. 19, Ning Shuang Road, Yuhua District, Nanjing to Jiangsu Yunzhi Hui Venture Capital Co., Ltd. for 119 million yuan [1] - This transaction is intended to address the issue of idle assets following relocation and to reduce operational costs [1] Group 2: Strategic Implications - The proceeds from the sale will be used to fund the operation of the new headquarters and the development of core business activities [1] - The decision aligns with the company's long-term strategy and benefits all shareholders [1]

证券代码：688580 证券简称：伟思医疗 公告编号：2025-045 南京伟思医疗科技股份有限公司 关于出售资产的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 交易简要内容:南京伟思医疗科技股份有限公司（以下简称："公司" 或"伟思医疗"）拟以总价人民币 11,900 万元的价格，将其持有的位于南京 市雨花台区宁双路 19 号 9 幢 的房屋及楼宇部分配套固定资产（以下简称"标 的资产"）转让给江苏云智汇创业投资有限公司（以下简称"本次交易"）。 交易实施尚需履行的审批及其他相关程序：本次交易已经公司第四届 董事会第八次会议审议通过，根据《上海证券交易所科创板股票上市规则》 的规定，该议案无需提交股东会审议。后续交易双方将按照签署的《南京市 存量房买卖合同》、《固定资产买卖合同》约定办理资产交付等事宜。 风险提示：经公司初步估算，本次交易预计对公司 2026 年度归属于 上市公司股东的净利润影响金额约为 1,000 万元（未经审计），对 2025 年当 期营业收入及净利润无任何影响，最终财务数据以公司 ...

每经头条（nbdtoutiao）——新能源重卡爆单了，11月销量同比增长178%！两班倒都供不应求，客户直 接进厂催单，这情景十年难遇 （记者 曾健辉） 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每日经济新闻 每经AI快讯，伟思医疗（SH 688580，收盘价：47.06元）12月22日晚间发布公告称，公司第四届第八次 董事会会议于2025年12月19日在公司会议室召开。会议审议了《关于出售资产的议案》等文件。 2024年1至12月份，伟思医疗的营业收入构成为：医疗器械占比95.03%，其他占比3.79%，其他业务占 比1.18%。 截至发稿，伟思医疗市值为45亿元。 ...

Core Viewpoint - Weisi Medical (688580.SH) has successfully completed the construction acceptance of its new headquarters, the "Weisi Medical Headquarters R&D Economic Park," which is expected to enhance operational efficiency and support the company's high-quality development [1] Group 1: New Headquarters Development - The new headquarters is located at No. 1 Shuo Guo Road, Yuhua District, Nanjing, covering an area of approximately 24,000 square meters with a total construction area of nearly 70,000 square meters [1] - The facility integrates high-end research and development, intelligent manufacturing, and modern office functions, significantly improving the office environment, production capacity, research infrastructure, and intelligence level compared to the current location [1] - The company plans to complete the overall relocation by the first half of 2026, which will provide a solid foundation for its high-quality development [1] Group 2: Asset Optimization and Financial Strategy - To optimize its asset structure and enhance resource allocation efficiency, the company plans to dispose of its current headquarters located at No. 19 Ning Shuang Road, Yuhua District, Nanjing [1] - The agreed total transfer price for the disposal of the property and associated facilities is RMB 119 million (equivalent to 11,900 million yuan) [1] - This disposal will help activate existing assets, address potential idle issues post-relocation, reduce operational costs, and recover funds for the new headquarters operations and core business development, aligning with the company's long-term strategy and benefiting all shareholders [1]

伟思医疗12月22日公告，为优化资产结构、提升资源配置效率并增强资金流动性，公司拟以总价1.19亿 元出售位于南京市雨花台区宁双路19号9幢的房屋及楼宇部分配套固定资产。本次交易预计对公司2026 年度归属于上市公司股东的净利润影响金额约为1000万元，对2025年当期营业收入及净利润无任何影 响。 ...